3
Access to Innovative Treatments Act of 2026
7/14/2026, 8:22 PM
Summary of Bill HR 9418
Congressional Summary of HR 9418
Access to Innovative Treatments Act of 2026
This bill requires the Centers for Medicare & Medicaid Services (CMS) to review adverse national coverage determinations of drugs under Medicare within 30 days of receiving a request to do so.
Specifically, the CMS must review within 30 days any denials or limitations of coverage that are inconsistent with the drug's approval by the Food and Drug Administration (FDA). The bill's requirements do not apply if the CMS already conducted such a review within a two-year period.
The bill also prohibits the CMS from applying prior coverage determinations that were made for drugs before they were approved by the FDA if such determinations are inconsistent with the drug's approval.
Read the Full Bill
Current Status of Bill HR 9418
Bipartisan Support of Bill HR 9418
Total Number of Sponsors
1Democrat Sponsors
1Republican Sponsors
0Unaffiliated Sponsors
0Total Number of Cosponsors
1Democrat Cosponsors
0Republican Cosponsors
1Unaffiliated Cosponsors
0Policy Area and Potential Impact of Bill HR 9418
Primary Policy Focus
HealthAlternate Title(s) of Bill HR 9418
Comments
Loretta Kelly
22 days ago
This bill is so dumb, like why they gotta mess with my Medicare drug coverage like this? It's gonna make it harder for me to get the meds I need, and that ain't right. They need to leave it alone and stop making things more complicated for us seniors. I ain't happy about this at all. #annoyed #Medicarewoes
